INTRODUCTION
the presence of interferon-g (IFNg) (Smith et al., 1994) . Similarly, HSV-1 persisted in the eyes of mice with a Herpes simplex virus type 2 (HSV-2) infects both the targeted deletion of the IFNg gene as compared to wildoral and genital mucosa of humans. In addition to initial type littermates in a model of herpetic stromal keratinitis replication and primary disease at the site of infection, (Bouley et al., 1995) . the virus can ascend sensory neurons, replicate, and
The immune mechanisms responsible for clearing become latent in the sensory ganglia. Reactivation of HSV-2 from the genital mucosa have not been well latent virus can result in recurrent disease at the site of studied. Protection of mucosal surfaces is generally initial infection. In addition to the pain associated with thought to be a function of secretory IgA. However, for HSV infections, the lesions associated with primary and pathogens such as HSV which can spread intracellurecurrent disease at the mucosal surface may also serve larly, cellular immune mechanisms are required for as efficient portals of entry for other sexually transmitted resolution of infection. It has been shown that adoptive diseases.
transfer of T lymphocytes from the draining lymph Clearance of virus from infected tissue is most often nodes of HSV-infected mice protected naive recipients T cell-mediated and involves both cytokine-mediated effrom a lethal challenge of the genital mucosa with HSVfector mechanisms and direct cytotoxic effects on virus-2 (McDermott et al., 1989) . More recently, it was shown infected cells. Clearance of acute HSV infections can be that intravaginal inoculation with an attenuated strain accomplished by either CD4 / or CD8 / T cells depending of HSV-2 resulted in the influx of HSV-specific Th 1-on variables such as virus dose, tissue site, or mouse type CD4 / T cells into vaginal tissue (Milligan and strain (Nash et al., 1987; Wildy and Gell, 1985; Leung et Bernstein, 1995a) , which apparently coincided with the al., 1984). A recent study using mice lacking CD4
/ or rapid resolution of the infection. In the current study, CD8
/ T cells as a result of targeted gene deletions dema murine model of genital HSV-2 infection was used onstrated that effective clearance from the skin was deto examine the role of IFNg in clearance of HSV-2 from pendent mainly on CD4 / T cells (Manickan and Rouse, the vaginal mucosa. Intravaginal inoculation with HSV-1995) . In a cutaneous model of HSV-1 infection using 2 resulted in sequential production of IFNg by NK cells genetically resistant mice, virus clearance could be efthen T lymphocytes; however, only IFNg produced prifected by either T cell subset and was dependent on marily by T cells after Day 3 played a role in rapid clearance of virus from the genital tract. The results of this study suggest that IFNg was not essential for the but was important for increasing the effectiveness of at 070Њ until plaque titration on Vero cell monolayers as described previously (Milligan and Bernstein, 1995b) . T cell-dependent mechanisms of virus clearance.
In vivo depletion of T cell subsets and neutralization MATERIALS AND METHODS of IFNg Mice
Mice were injected intraperitoneally (i.p.) with 1.5 mg Female BALB/cAnNHsd (Harlan-Sprague-Dawley, purified GK1.5 or 2.43 antibodies on Days 5,4,2, and 1 Inc., Indianapolis, IN) were used between 6 and 15 prior to HSV-2 inoculation, on the day of inoculation, and weeks of age. Age-matched, uninoculated mice were every other day thereafter to Day 6. Mice treated with a used as controls. mixture of 1.5 mg each of GK1.5 and 2.43 were treated to Day 8. Splenic and gLN lymphocytes from antibodyVirus treated and control-treated mice were analyzed on the day of inoculation by flow cytometry to determine in vivo The bromodeoxyuridine-resistant mutant, HSV-2 333 tk 0 (Stanberry et al., 1985) , was grown and titered as depletion. GK1.5 antibody treatment typically resulted in 80-87% depletion of CD4 / gLN T cells and treatment described previously (Milligan and Bernstein, 1995b) . HSV-2 strain 186 was obtained from Dr. Lawrence Stanwith 2.43 antibody typically resulted in complete (100%) CD8 / T cell depletion. Treatment with a cocktail of GK1.5 berry (Children's Hospital Medical Center, Cincinnati, OH) and used as a challenge virus in these studies as and 2.43 antibodies resulted in an 87% depletion of splenic CD3 / lymphocytes. In preliminary experiments, described previously (Milligan and Bernstein, 1995b) .
virus clearance in mice treated with PBS or an irrelevant Antibodies rat IgG monoclonal antibody was not different, therefore PBS was used as a control treatment in these studies. Rabbit anti-asialo GM1 was purchased from Wako IFNg was neutralized in vivo by daily i.p. injection of Chemicals USA, Inc. (Richmond, VA). Hybridomas 2.43 1.5 mg purified XMG1.2 antibody from the day prior to (anti-murine CD8), GK1.5 (anti-murine CD4), R46A2 (antiinoculation through Day 7 after inoculation. In some exmurine IFNg), and HO2.2 (anti-murine CD8) were obperiments, treatment of mice was performed on Days 3 tained from the American Type Culture Collection (Rockthrough 7 after inoculation. NK cells were depleted by ville, MD). Hybridoma XMG1.2 (anti-murine IFNg) was intravenous injection of 50-75 ml of rabbit anti-asialo obtained with permission of Dr. Tim Mosmann (Univ. of GM1 antibody (dosage based on manufacturer's antibody Alberta, Alberta, Canada). Hybridomas were grown to log titration) 2 days before and 1 day following intravaginal phase in RPMI supplemented with 20% fetal calf serum inoculation with HSV-2 tk 0 . (FCS) (GIBCO Life Technologies, Gaithersburg, MD) and then seeded into 150-cm 2 flasks containing Hybridoma Depletion of T lymphocyte subsets in vitro Serum Free Media (GIBCO Life Technologies). After 5-7 days, cells were removed by centrifugation and anti-CD4 / or CD8 / T cells were depleted as described previously (Milligan and Bernstein, 1995a) with optimal body was precipitated from supernatants with ammonium sulfate (Sigma, St. Louis, MO), dissolved in distilled dilutions of GK1.5 or HO2.2 antibody, respectively, and low tox M rabbit complement (Cedarlane Laboratories, water, and dialyzed extensively against phosphate-buffered saline (pH 7.2). Antibody purification was monitored Ltd., Hornby, Ontario, Canada). Cells were washed three times and counted prior to culture. by SDS-PAGE and antibody concentration was determined by UV spectrometry.
IFNg ELISPOT assay Genital herpes inoculation and vaginal virus titration
A modification of the procedure described previously (Milligan and Bernstein, 1995a) was used in these studMice were inoculated intravaginally with HSV-2 333 tk 0 or HSV-2 186 by a modification of the method described ies. Briefly, single cell suspensions of gLN lymphocytes from uninoculated and HSV-2 tk 0 -inoculated mice were previously (Milligan and Bernstein, 1995b) . Briefly, mice which had been treated twice in a 1-week period with resuspended to 10 6 cells/ml in RPMI supplemented with 10% FCS. One hundred microliters of this cell suspension 6a-methyl-17a-hydroxyprogesterone acetate (Sigma) at 3 mg/mouse were preswabbed with a cotton pledget, and a series of threefold dilutions was plated in duplicate on nitrocellulose filter plates (Millipore Corp., Bedford, anesthetized with sodium pentobarbital, and inoculated with 20 ml of virus suspension (5 1 10 5 -10 6 PFU HSV-2 MA) coated previously with 10 mg/ml purified R4-6A2 antibody. Plates were incubated overnight at 37Њ, washed 333 tk 0 ; 10 6 PFU HSV-2 186) soaked onto a type 2 calgiswab. Vaginal virus titers were monitored by swabbing thoroughly to remove cells, and incubated with rabbit anti-murine IFNg (Biosource International, Camarillo, CA) the vagina with a moist type 2 calgiswab which was immediately added to 1.0 ml media followed by storage followed by peroxidase-conjugated goat anti-rabbit IgG (United States Biochemical Corp., Cleveland, OH). Plates was neutralized in vivo by daily treatment of mice with anti-IFNg antibody beginning the day prior to HSV-2 tk 0 were then washed and developed with 3-amino-9 ethylcarbazole substrate and peroxide. Spots representing infection. IFNg was detected by ELISA in vaginal washes from control-treated but not in anti-IFNg-treated mice specific cytokine-secreting cells were counted with the aid of a dissecting microscope.
through Day 9 postinoculation (Table 1) . No significant differences in vaginal virus titers of control-treated and IFNg ELISA anti-IFNg-treated mice were observed through the first IFNg was detected in vaginal secretions by washing 3 days of infection ( Fig. 2A ). Control-treated mice rapidly the vagina twice with 60 ml Hank's balanced salt solution cleared virus beginning on Day 4 while virus titers deplus 5% FCS. The wash was clarified by microcentrifugacreased more slowly in anti-IFNg-treated mice ( Fig. 2A ), tion and stored at 070Њ until quantitation by ELISA. ELISA resulting in an ultimate delay in viral clearance of approxplates were coated with purified R4-6A2 (anti-murine imately 2 days. IFNg) at 5 mg/ml and blocked with PBS plus 5% bovine
To determine if the IFNg produced during the first 3 serum albumin. A series of twofold dilutions of rIFNg days of infection was sufficient to effect the rapid clearstandards (Sigma) at concentrations from 125 to 0.12 ance of virus from the vagina, anti-IFNg treatment was Units/ml and undiluted vaginal washes were plated in initiated 3 days after genital inoculation at a time coinciduplicate and incubated overnight at 4Њ. Plates were then dent with the end of the NK cell IFNg production (Days washed and developed with the same reagents as for 2-3) but before T cell-mediated IFNg production began IFNg ELISPOT plates except that o-phenylenediamine (Days 4-7). No significant differences in the kinetics of dihydrochloride (OPD)/peroxide (Sigma) was used as the virus clearance from the vagina were observed between substrate. The limit of detection of the assay was considcontrol-treated and anti-IFNg-treated mice through the ered to be the last concentration of rIFNg standard which first 4 days of infection (Fig. 2B ). However, viral titers gave an OD 490 value greater than the mean plus 3 stanwere significantly elevated in treated mice on Days 5-7 dard deviations of the background (media alone) wells.
and, similar to the previous experiment ( Fig. 2A) , clearance was delayed by about 2 days.
Statistical analysis

Data were analyzed by unpaired, two-tailed t tests or
Clearance of HSV-2 from the vaginal mucosa requires one-way analysis of variance with the Bonferroni correc-T cells but not NK cells tion for multiple groups as appropriate.
To determine if NK cells played a role in clearance RESULTS of HSV-2 from the vaginal mucosa, BALB/c mice were depleted of NK cells by treatment with anti-asialo GM1 IFNg production in mice infected vaginally antibody prior to genital HSV-2 tk 0 inoculation. For comwith HSV-2 tk 0 parison, separate groups of mice were control treated The production of IFNg at the vaginal mucosal surface or made deficient in T lymphocytes by treatment with following genital inoculation with HSV-2 tk 0 was biphasic antibodies to CD4 and CD8 (Fig. 3) . No significant differ- (Fig. 1) . The first IFNg peak occurred on Day 2 and fell ences in mean vaginal virus titers were observed among to low levels on the third day after inoculation. Mice NK cell-depleted, T cell deficient, and control-treated depleted of NK cells by in vivo treatment with anti-asialo mice for the first 3 days of infection (Day 1, P Å 0.47; GM1 antibody produced significantly lower amounts of Day 2, P Å 0.13; Day 3, P Å 0.8). However, the mean IFNg in vaginal secretions on Day 2 than control mice vaginal virus titer in anti-CD4/CD8 antibody-treated mice treated with PBS or normal rabbit serum (P õ 0.01) (Fig. was significantly greater than that of the other groups 1). By contrast, Day 2 vaginal IFNg levels in mice deon Day 4 (P õ .05). Further, NK cell-depleted mice and pleted of T cells were not significantly different than control-treated mice cleared the virus rapidly on Days 5 those of control-treated mice. IFNg levels rose again and 6, whereas virus persisted in vaginal secretions of after Day 4 in control-treated mice, peaked on Day 5, T cell-deficient mice through at least Day 10. and fell to low levels on Day 8. IFNg was detected at comparable levels in NK cell-depleted mice on these Role of CD4 / and CD8 / T cells in IFNg production days but was undetectable in Day 5 vaginal secretions and clearance of virus from genital mucosa of T cell-depleted mice and was detected only at very BALB/c mice were depleted of CD4 / or CD8 / T cells low levels on Day 6-8 postinoculation.
prior to genital inoculation with HSV-2 tk 0 to examine In vivo neutralization of IFNg results in delayed the importance of these T cell subsets for vaginal IFNg clearance of vaginal HSV-2 tk 0 production and virus clearance from the vaginal mucosa. Treatment of mice with anti-CD4 antibody resulted in To examine the role of IFNg in clearance of HSV-2 from the genital mucosa during a primary infection, IFNg altered kinetics of vaginal virus clearance (Fig. 4A ). There Mice were treated with antibodies to CD4 and CD8 (triangles), anti-asialo GM1 (diamonds), or normal rabbit serum (squares) as described under Materials and Methods. Vaginal washes were taken from BALB/c ANnHsd at 24-hr intervals after genital HSV-2 tk 0 inoculation. The concentration of IFNg in vaginal washes was determined by ELISA (limit of detection 0.5 U/ml). Results are expressed as the mean Units of IFNg/ml //0 SEM for 9 anti-asialo GM1-treated, 5 anti-CD4/CD8-treated, and 5 normal rabbit sera-treated mice. Less than 0.5 U/ml IFNg were detected in vaginal washes from 8 uninoculated mice (not shown). Comparable results were obtained in a separate experiment. was no significant difference in viral titers between antiMice depleted of CD8 / T cells by in vivo treatment with anti-CD8 antibody cleared virus from the vaginal CD4-treated and control-treated mice on Days 1-3 but virus clearance was delayed and virus persisted in vagimucosa and resolved the infection with similar kinetics as control-treated mice (Fig. 4B) . Further, IFNg-secreting nal secretions through Day 8 in anti-CD4-treated mice.
A reduction (87%) in the number of IFNg-secreting cells were detected in the gLN of these mice in numbers comparable to PBS-treated controls (Table 2 ) and the cells in the genital lymph nodes (gLN) of anti-CD4-treated mice as compared to control-treated mice was detected majority of these cells were eliminated by in vitro treatment with anti-CD4 and complement (Table 3 ). on Day 6 following HSV-2 tk 0 infection (Table 2 ). The remaining IFNg-secreting cells from these mice were predominantly CD8 / as treatment of gLN lymphocytes DISCUSSION from these mice with anti-CD8 antibody and complement resulted in nearly complete (88%) depletion of IFNg-seThe immune mechanisms directly responsible for virus clearance are not well understood and may depend on creting cells (Table 3) . Treatment of the same population of cells with anti-CD4 antibody and complement did not variables such as the virus type, dose, and route of inoculation. Historically, virus-specific CD8 / T cells have been further reduce the number of IFNg-secreting cells. et al., 1992) , and which develop following HSV-2 infection (Jennings et al., 1985) , presumably due to the ability of HSV-2 to HSV-1 (Smith et al., 1994) . The results of the present study demonstrate that IFNg augments T cell-mediated decrease the surface expression of MHC class I molecules (Jennings et al., 1985; York et al., 1994) . virus clearance but is not essential for the ultimate clearance of HSV-2 from the vaginal epithelia.
1993), murine cytomegalovirus (Lucin
Depletion of NK cells with the consequent loss of early IFNg production (Fig. 1) did not significantly affect the During the first 3 days of infection, IFNg was apparently produced predominantly by NK cells while IFNg rate of HSV-2 clearance from the vagina (Fig. 3 ). In contrast, neutralization of IFNg beginning Day 3 after inocudetected on Days 4 -7 was produced primarily by T cells (Fig. 1) . Because greater numbers of IFNg secrelation effectively delayed virus clearance (Fig. 2B) , suggesting that CD4 / T cell-derived IFNg and not NK cellting cells were detected in genital lymph nodes from CD8
/ , compared to CD4 / T cell-depleted mice (Tables  produced IFNg played a role in rapid virus clearance. NK cell-produced IFNg has been shown to play an im-2 and 3), and CD4 / T cell depletion, but not CD8 / T cell depletion, resulted in low levels of IFNg in vaginal portant role in skewing the developing immune response to a Th1-type response in Leishmania major infections secretions on Days 4 -5 (G. Milligan, unpublished results), it seems most likely that Th1-type CD4 / T cells (Scharton and Scott, 1993) . However, in preliminary experiments, depletion of NK cells resulted in severe dampwere primarily responsible for the second period of IFNg-secretion. These data are in agreement with our ening of early IFNg release but did not change the ratio of IFNg secreting T cells to IL-4 secreting T cells followprevious studies, demonstrating the appearance of HSV-specific, Th1-type CD4 / T cells in vaginal tissue ing HSV-2 tk 0 vaginal inoculation (G. Milligan, unpublished results). Therefore, in these studies of a primary on Day 5 after infection (Milligan and Bernstein, 1995a) but differ from those of Smith et al. (1994) in which HSV-2 infection we could not detect a role for NK cells in virus clearance from the vagina or in influencing the either CD4
/ or CD8 / T cells apparently could provide the IFNg required for clearance of HSV-1 in a cutanature of the developing HSV-specific CD4 / T cell response. It remains possible that NK cells may have influneous infection model. The failure of CD8 / T cell depletion to affect virus clearance kinetics (Fig. 4B) as enced the local vaginal immune response in other ways. For example, based on the ability of IFNg to enhance well as the meager CD8
/ T cell response to HSV-2 in this model (Milligan and Bernstein, 1995a ) may reflect expression of antigens such as mouse endothelial cell antigen 325 (Duijvestijn et al., 1986) , intercellular adhelow numbers of HSV-specific CD8
/ T cell precursors sion molecule 1 (ICAM 1), and platelet endothelial cell prevent, virus clearance ( Figs. 2A and 2B ). Similar results were obtained using BALB/c mice with a targeted adhesion molecule 1 (PECAM1) on high endothelial venules (Tang and Hendricks, 1996) , it is possible that NKdeletion of the IFNg gene (IFNg 0/0) where the delay of clearance was approximately 1 day as compared produced IFNg may play a role such as enhancing recruitment of lymphocytes and inflammatory cells into the to control animals (G. Milligan, unpublished results). These results are different than those obtained by infected mucosa.
Neutralization of IFNg in vivo delayed, but did not Smith et al. (1994) and Bouley et al. (1995) in which in (Croen, 1993) and TNFa administration to in- T cell-depleted mice because IFNg-secreting CD8 / T respectively. Although the difference in requirement for IFNg in viral clearance among these studies may cells were detected in CD4 / T cell-depleted mice (Tables 2 and 3) and mice depleted of both T cell subsets reflect a difference in sensitivities of HSV-2 and HSV-1 to direct or indirect effects of IFNg, it is also possible shed virus through Day 10 (Fig. 3) . Taken together, these results are consistent with the hypothesis that that the disparate results reflect only a difference in viral clearance kinetics. That is, virus might have ultiboth T cell subsets can effect virus clearance during an acute HSV-2 vaginal infection but that CD4 / T cells mately been cleared in the studies of Smith et al. (1994) and Bouley et al. (1995) but at times later than were assayed. It is also possible that other cytokines capa- cells (Kimura et al., 1994; Klotzbucher et al., 1990) or in synergy with other cytokines such as TNFa, IFNa, or a Groups of 4 BALB/c mice were treated in vivo with PBS (Control), anti-CD8 (2.43), or anti-CD4 (GK1.5) as described under Materials and IFNb (Feduchi and Carrasco, 1991; Balish et al., 1992;  Methods. Genital lymph node cells were harvested on Day 6 after Czarniecki et al., 1984; Zerial et al., 1982) seem to argue against IFNg acting directly as an antiviral
